ArticleJournal of pharmaceutical policy and practice2025
Stakeholder engagement and pharmaceutical pricing regulation: a qualitative inquiry.
Article in Journal of pharmaceutical policy and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmaceutical import landscape in Ethiopia: a cross-sectional study of importers' perspectives on business and regulatory challenges.Tropical medicine and health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Medicine affordability is a critical component of a country's redistributive health policies aimed at ensuring equitable access to healthcare. This study aims to investigate key stakeholders' perspectives on pharmaceutical pricing control in Malaysia as the country is moving towards sustainable healthcare. Methods: Semi-structured interviews ( Results: The findings indicate a range of opinions among stakeholders, with most generally favouring the implementation of pharmaceutical pricing regulation. However, concerns have been raised about potential cost transfer, where medication expenses may be shifted to other medical services. Furthermore, there are apprehensions that price controls could adversely affect the profitability of the pharmaceutical industry and impede the development of innovative drugs. Proposed measures include the introduction of price controls and the enhancement of price transparency for specific medications used to address acute and major health issues. Conclusion: Our study contributes to the current understanding of the formation of public health policies to improve social welfare through stakeholder engagement to ensure that it reflects public needs. Malaysia is a valuable example for developing countries seeking equitable access to manage rising healthcare costs. The study is crucial for understanding country-specific experiences and stakeholders' views on pharmaceutical pricing regulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.